EMA Authorised: Axumin (fluciclovine (18F)) — Blue Earth Diagnostics Ireland Ltd

View source ↗

Summary

The European Medicines Agency authorised Axumin (fluciclovine (18F)) for radionuclide imaging in prostate cancer, marking its market access in the EU. The decis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Axumin (fluciclovine F-18)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms;Radionuclide Imaging. MAH: Blue Earth Diagnostics Ireland Ltd. Decision date: 26/03/2026